The BBRC, CITA-Alzheimer and Fundació ACE share their experience in EPAD
The European project EPAD (European Prevention of Alzheimer's Dementia) is made up of 39 entities across Europe, determined to expand the knowledge about the preclinical phase of Alzheimer's disease and thus be able to prevent dementia before the symptoms appear. Three Spanish centers for leading Alzheimer's research are participating in the project: the BarcelonaBeta Brain Research Center (BBRC) of the Pasqual Maragall Foundation, the CITA Alzheimer Foundation, and Fundació ACE - Alzheimer Treatment & Research Center.
Dr. Karine Fauria, manager of scientific resources at the BBRC, Dr. Pablo Martínez-Lage, scientific director of the CITA Foundation, and Dr. Mercè Boada, medical director of Fundació ACE, comment in the following video their experience in EPAD.
Pasqual Maragall Foundation
Currently, the BBRC is the European center that has recruited the most participants for the project, with more than 250 people who regularly perform cognition, neuroimaging, clinical and nursing tests at the headquarters of the Pasqual Maragall Foundation. A milestone that Dr. Fauria attributes to the great commitment and predisposition of the Alfa Study participants: "we have an extraordinary population because they come from the Alfa Study, in which the majority of participants are children of people with Alzheimer's disease. This is why they fostered an extreme motivation, as well as a generosity and a capacity to make fantastic efforts around the investigation".
From the 1,600 people from all over Europe who participate in the EPAD cohort, more than 230 participants were recruited at the CITA Foundation in San Sebastián, reaching the second position in terms of recruitment within the project. According to Dr. Martínez-Lage, the possibility of entering a large-scale European consortium has been "the finishing touch" for the longitudinal Alzheimer prevention cohort that they started 9 years ago: "We are contributing to the advancement of science and medicine in a large European study. In addition, Dr. Martínez-Lage highlights, above all, the possibility that Basque participants will have to reach the intervention phase, as well as try drugs and new preventive strategies.
Other research centers are also entering the study recently, such as Fundació ACE, which joined the project in February of this year. In the same video, recorded at one of the project meetings held in Berlin, Dr. Boada expressed her gratitude for entering into a "European project that tracks people interested in participating in Alzheimer's clinical trials in order to offer a possible treatment".